![Michael Meyers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Meyers
Directeur/Membre du Conseil chez
NUVALENT, INC.
Fortune : 948 250 $ au 31/05/2026
Profil
Michael L.
Meyers is currently an Independent Director at Nuvalent, Inc. since 2022 and Vice President at Janssen Research & Development LLC.
Formerly, Dr. Meyers was Vice President-GU Oncology & Compound at Johnson & Johnson, Chief Medical Officer & Senior Vice President at Syndax Pharmaceuticals, Inc. from 2016 to 2022, Chief Medical Officer at Flare Therapeutics, Inc. from 2023 to 2026, a Member at Memorial Sloan Kettering Cancer Center, and Vice President-Oncology Scientific Innovation at Johnson & Johnson Innovation LLC.
Dr. Meyers earned a doctorate from Albert Einstein College of Medicine, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/06/2026 | 8 590 ( 0,01% ) | 948 250 $ | 31/05/2026 |
Postes actifs de Michael Meyers
| Sociétés | Poste | Début |
|---|---|---|
| NUVALENT, INC. | Directeur/Membre du Conseil | 04/10/2022 |
Janssen Research & Development LLC
 Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Provides research and development medicines and solutions to other medical needs | Corporate Officer/Principal | - |
Anciens postes connus de Michael Meyers
| Sociétés | Poste | Fin |
|---|---|---|
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of small molecule medicines | Directeur Technique/Scientifique/R&D | 31/01/2026 |
| SYNDAX PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2022 |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates cancer hospital | Corporate Officer/Principal | - |
Johnson & Johnson Innovation LLC
 Johnson & Johnson Innovation LLC Medical/Nursing ServicesHealth Services Provides healthcare solutions and services | Corporate Officer/Principal | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Formation de Michael Meyers
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
18
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates cancer hospital | Health Services |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Research & Development LLC
Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Provides research and development medicines and solutions to other medical needs | Commercial Services |
Johnson & Johnson Innovation LLC
Johnson & Johnson Innovation LLC Medical/Nursing ServicesHealth Services Provides healthcare solutions and services | Health Services |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of small molecule medicines | Health Technology |
